T2 Biosystems, Lexington, Mass, a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, recently announced that its board of directors has appointed diagnostics industry veteran John Sperzel as president and chief executive officer. Sperzel, who will also join the board of directors, succeeds John McDonough, who will continue with his board leadership role, serving as nonexecutive chairman.
“I am honored to join T2 Biosystems as its second CEO at this important transitional moment,” says Sperzel. “This is an exciting time for the company, in the battle against sepsis, and I look forward to leading the business to its next chapter of growth. Sepsis represents $27 billion in annual US healthcare costs and claims more lives annually than lung cancer, colorectal cancer, and breast cancer combined. T2 Biosystems has the only FDA-cleared diagnostic tests to detect sepsis-causing pathogens directly from whole blood, which can save lives, reduce healthcare costs, and fight antimicrobial resistance.”
For further information, visit T2 Biosystems.
